Anemia

Study: Long-Acting ESA Users Might Have Worse Survival

Publish Date April 25, 2019

In a nationwide study of Japanese hemodialysis patients, long-acting ESA use was associated with increased rates of cardiovascular and noncardiovascular mortality compared with short-acting ESA use.

Turmeric Supplementation Linked to Patient’s Iron Deficiency Anemia

Publish Date April 12, 2019

The physician, who was experiencing an osteoarthritis flare following steroid therapy, began self-treating with turmeric extract capsules.

Study: ESAs Improve HRQoL, Lower Costs in the Dialysis Population

Publish Date April 1, 2019

In a systematic review, not treating anemia in patients on dialysis turned out to be more costly than treatment with erythropoiesis-stimulating agents.

Hepcidin a Possible Marker of ESA Resistance

Publish Date March 28, 2019

In a study, hepcidin and serum hsCRP predicted the erythropoietin resistance index in patients on hemodialysis.

Daprodustat Shows Short-Term Efficacy for Anemia in CKD, HD

Publish Date March 27, 2019

Daprodustat maintained hemoglobin levels within a target range a majority of the time in patients with nondialysis chronic kidney disease and those on hemodialysis.

Molidustat Effective, Well-Tolerated for Anemia Treatment Long Term

Publish Date March 25, 2019

In 2 extension studies, molidustat appeared as effective as darbepoetin and epoetin in patients with non-dialysis chronic kidney disease or on hemodialysis patients.

Anemia in CKD Managed Effectively With Enarodustat

Publish Date February 6, 2019

The medication showed promise as correction and maintenance therapy in a phase 2b trial of non-dialysis CKD patients with anemia.

Study: ESA Use Prior to Dialysis Transition Does Not Improve Outcomes

Publish Date February 5, 2019

Study finds no decrease in the risk for mortality, myocardial infarction, or heart failure in the first 180 days.

Iron Profile Differs for Hemodialysis Patients With ADPKD

Publish Date February 4, 2019

Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.

Statins May Improve ESA Response in CKD Patients

Publish Date January 25, 2019

Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients.